

# Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

NCT06887907

---

**Status** RECRUITING  
**Sponsor** University Hospital, Toulouse  
**Enrollment** 40 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Sickle cell disease SS or S-bé $\alpha$ ° thalassemia
- Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome
- Age  $\geq$  18 years old

### Exclusion (4)

- Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplastic syndrome, myeloproliferative syndrome)
- Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23
- Anti-platelets agents
- Red blood cell exchange or transfusion  $<$  3 months

## Locations (1 total)

---

CHU de Toulouse, Toulouse, France, France